3
Clinical Trials associated with L-asparaginase (Chandra Bhagat Pharma Ltd.)Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute
Understand the dynamics of elimination of MRD in adult patients with standard-risk LAL treated with a pediatric protocol.
Start Date01 Jan 2008 |
Sponsor / Collaborator- |
LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia
The study objective is to improve the global results obtained with LAL-AR-93 study, reaching an event free survival between 60-70%.
Identify patients with bad prognosis, with minimal residual disease,who can benefit of allogenic bone marrow transplantation
Start Date01 Jun 2005 |
Sponsor / Collaborator- |
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive
Due to ALL Ph+ patients should receive a different treatment, is proposed a therapeutical protocol with: intensification treatment of induction to increment the CR rate, allogenic transplantation in first CR, autologous transplantation follow by alfa interferon in patients cannot done allogenic transplantation.
Start Date01 Jan 2000 |
Sponsor / Collaborator- |
100 Clinical Results associated with L-asparaginase (Chandra Bhagat Pharma Ltd.)
100 Translational Medicine associated with L-asparaginase (Chandra Bhagat Pharma Ltd.)
100 Patents (Medical) associated with L-asparaginase (Chandra Bhagat Pharma Ltd.)
1
Literatures (Medical) associated with L-asparaginase (Chandra Bhagat Pharma Ltd.)Principal biochemical characteristics of the EC-2 L-asparaginase from Escherichia coli AT.
100 Deals associated with L-asparaginase (Chandra Bhagat Pharma Ltd.)